The primary end point was intracranial progression-free survival (iPFS) with secondary end points of extracranial progression-free survival (ePFS) and overall survival (OS). Objective intracranial response rate was defined as the proportion of patients who achieved CR or PR. Clinical benefit rate was the proportion of patients with stable disease for ≥6 months or achieved CR or PR among all evaluable patients. Patients who had stable disease for ≥6 months were considered unevaluable for that measure.